Squamous Cell Carcinoma Subtype Classification via Gene Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a reliable and precise way to evaluate the efficacy of chemoradiotherapy for squamous cell carcinoma, particularly in identifying sensitive subtypes and predicting prognosis, due to insufficient analysis of esophageal squamous cell carcinoma samples.
Innovation Solution
An unsupervised cluster analysis based on comprehensive gene expression profiles identifies subtypes correlated with treatment prognoses, focusing on the SIM2 and FOXE1 genes and their co-expressed genes to determine chemoradiotherapy sensitivity, enabling high-precision evaluation of chemoradiotherapy efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional gene expression analysis methods are used for squamous cell carcinoma, then general cancer treatment guidelines can be followed, but the precision of chemoradiotherapy efficacy evaluation is insufficient
Solution Approach 1:
The invention segments squamous cell carcinoma into five distinct molecular subtypes (subtype-1 through subtype-5) based on gene expression profiles. This segmentation allows for precise identification of chemoradiotherapy-sensitive subtypes (subtype-2, subtype-3, subtype-5) versus resistant subtypes (subtype-1, subtype-4), thereby improving both measurement precision of treatment efficacy and reliability of prognosis prediction.
Solution Approach 2:
The invention changes the evaluation parameter from general cancer treatment response to specific gene expression profile analysis. By measuring expression levels of specific genes (including SIM2 and its co-expressed genes, as well as FOXE1 and its co-expressed genes), the method achieves high-precision evaluation of chemoradiotherapy efficacy that was not possible with conventional approaches.
2Measurement precision
If comprehensive gene expression profile analysis is performed to identify subtypes, then chemoradiotherapy sensitivity can be accurately predicted, but the complexity of the evaluation method increases
Solution Approach 1:
The invention extracts specific key genes and gene groups from the comprehensive gene expression profile that are most predictive of chemoradiotherapy response. By focusing on specific genes (SIM2, FOXE1 and their co-expressed genes) rather than analyzing all genes equally, the method maintains high prediction accuracy while reducing evaluation complexity.
Solution Approach 2:
The invention performs partial analysis by selecting and analyzing only the most relevant gene groups associated with chemoradiotherapy sensitivity. Rather than requiring comprehensive analysis of all possible genes, the method focuses on specific gene groups that provide sufficient predictive power, thereby balancing accuracy with practical feasibility.
Data Source
AI summary
A method for evaluating an efficacy of a chemoradiotherapy against squamous cell carcinoma comprises the following steps (a) to (c):(a) detecting an expression level of at least one gene selected from a SIM2 gene and genes co-expressed with the SIM2 gene in a squamous cell carcinoma specimen isolated from a subject;(b) comparing the expression level detected in the step (a) with a reference expression level of the corresponding gene; and(c) determining that an efficacy of a chemoradiotherapy against squamous cell carcinoma in the subject is high if the expression level in the subject is higher than the reference expression level as a result of the comparison in the step (b).